Advertisement

Topics

PubMed Journals Articles About "PTHrP And Osteoporosis" RSS

14:37 EST 16th December 2018 | BioPortfolio

PTHrP And Osteoporosis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest PTHrP And Osteoporosis articles that have been published worldwide.

More Information about "PTHrP And Osteoporosis" on BioPortfolio

We have published hundreds of PTHrP And Osteoporosis news stories on BioPortfolio along with dozens of PTHrP And Osteoporosis Clinical Trials and PubMed Articles about PTHrP And Osteoporosis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PTHrP And Osteoporosis Companies in our database. You can also find out about relevant PTHrP And Osteoporosis Drugs and Medications on this site too.

Showing "PTHrP Osteoporosis" PubMed Articles 1–25 of 530

Case report: Penile squamous cell carcinoma associated with severe hypercalcemia and high levels of Parathyroid Hormone related Peptide (PTHrP) expressed in metastatic skin tissue.

It is known that high levels of parathyroid hormone-related protein (PTHrP) correlate with a bad prognostic in malignancies. Here we present a patient with advanced penile cancer (PC) without antecedents of HPV infections and bone metastases but with severe hypercalcemia. By qPCR we observed high levels of PTHrP mRNA in metastatic cutaneous tissue. This is the first reported case in Argentina of hypercalcemia induced by PTHrP in human PC. Furthermore, the association of PTHrP and this disease through qPCR a...


Gestational Gigantomastia Complicated by PTHrP-mediated Hypercalcemia.

Gestational gigantomastia is an uncommon condition characterized by abnormal and excessive growth of breast tissue during an otherwise uncomplicated pregnancy. Gestational gigantomastia may be accompanied by hypercalcemia, which in some cases has been associated with elevated serum levels of PTHrP. The source of the PTHrP in these cases has been suggested to be the enlarged breasts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.


World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Author Index.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Poster Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Plenary Lectures Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Educational Lecture Abstract.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Satellite Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Oral Communication Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Meet-the-Expert Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Non-Sponsored Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESCEO Symposia Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): IOF-ESCEO Symposium Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESCEO-WHO Symposia Abstracts.

Prevalence of osteoporosis and osteopenia in patients occupationally active.

Osteoporosis is a public health problem worldwide, affecting more than 200 million people. It is estimated that 30 to 50% of postmenopausal women suffer from it. According to the International Osteoporosis Foundation (IOF), osteoporosis is a disease characterized by a decrease in the density and quality of bones. The objective of this work was to know the prevalence of osteoporosis and osteopenia in healthy active workers.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): EUGMS-ESCEO-IOF Symposium Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): ESPRM-ESCEO-IOF Symposium Abstracts.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2018): Committee of National Societies Abstracts.

Osteoporosis and dry eye syndrome: A previously unappreciated association that may alert active prevention of fall.

Osteoporosis is a multifactorial disease associated with inflammation and hormone imbalance. It is noteworthy that dry eye syndrome shares a similar pathophysiology with osteoporosis. Both diseases are more prevalent among the elderly and females. Dry eye syndrome can result in impaired vision, which increases the risk of fall and fracture when osteoporosis exists. In this study, we investigated whether osteoporosis is associated with an increased risk of developing dry eye syndrome.

Induced Lesion and Inhibited Ihh-PTHrP Signalling Pathway Activity in the Articular Cartilage of Rats Caused by T-2 toxin.

This study aims to investigate the role of Ihh-PTHrP signalling pathway in the articular cartilage injury of rats caused by T-2 toxin. Sixty male Wistar rats were randomly divided into four groups: group A, normal diet; group B, normal diet plus the dissolvent (0.9% sodium chloride sterile aqueous solution containing ethanol); group C, normal diet plus low T-2 toxin (0.1 mg/kg BW/day) and group D, normal diet plus high T-2 toxin (0.2 mg/kg BW/day) by intragastric administration daily for 4 weeks. Histologic...

Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions.

Osteoporosis is a common disorder affecting populations worldwide. In Latin America, an aging population combined with limited health care resources result in osteoporosis quickly becoming a condition of considerable magnitude with disproportionate morbidity and mortality.

Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.

The long-term impact of hormone therapy for breast cancer on risk of osteoporosis and the extent to which bone screening recommendations are implemented in daily practice remain unknown. We found that the aromatase inhibitor-induced risk of osteoporosis did not continue in the off-treatment follow-up. Adherence to screening recommendations was suboptimal.

The prevalence of overtreatment of osteoporosis: results from the PAADRN trial.

Overtreatment of osteoporosis increases costs and puts patients at unnecessary risk of experiencing adverse drug events. In the Patient Activation After DXA Receipt Notification (PAADRN) trial, we found that 8% of individuals with no indication for therapy were recommended a new osteoporosis medication or continuation of an existing medication.

Opportunistic Screening for Osteoporosis Using Computed Tomography: State of the Art and Argument for Paradigm Shift.

Osteoporosis is disproportionately common in rheumatology patients. For the past three decades, the diagnosis of osteoporosis has benefited from well-established practice guidelines that emphasized the use of dual x-ray absorptiometry (DXA). Despite these guidelines and the wide availability of DXA, approximately two thirds of eligible patients do not undergo testing. One strategy to improve osteoporosis testing is to employ computed tomography (CT) examinations obtained as part of routine patient care to "...

A specific haplotype in potential miRNAs binding sites of secreted frizzled-related protein 1 (SFRP1) is associated with BMD variation in osteoporosis.

Osteoporosis is an important multifactorial disease which is largely influenced by Wnt signaling pathway. Considering regulatory single nucleotide polymorphisms in Wnt signaling pathway may pave the road of understanding the genetic basis of predisposition to osteoporosis. The aim of this study was to determine the possible association between variants of SFRP1 and WNT5b, and osteoporosis incidence risk.


Advertisement
Quick Search
Advertisement
Advertisement